Your support fuels our research to #EndALS! Donate Now
Quick Info
Status
Currently Recruiting
Phase
2
Trial Type
Interventional
Treatment Type
Drug Trials
Randomization
Unknown
Enrollment
18
Start Date
1/27/2021
Contact Information
    Contact information unknown.
Locations
United States, Illinois
Northwestern University, Chicago, IL, 60611, United States
Contact: Benjamin Joslin   312-503-7504   ben.joslin@northwestern.edu
United States, Texas
Austin Neuromuscular Center, Austin, TX, 78756, United States
Contact: Michael Chiodo   512-920-0140   michael@austinneuromuscle.com
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
N/A
Months Since Onset
Number of months since first symptoms of ALS.
3 Years
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
N/A
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
N/A
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Yes
Open Label
No
Update Notes
Contact updates
5/19/2021
Study recruiting
2/22/2021
Study start and contact info updated
1/11/2021
No significant updates
12/8/2020

Other Information

Purpose
The purpose of this study is to evaluate the safety of intramuscular (IM) administration of Engensis in Participants with Amyotrophic Lateral Sclerosis (ALS) as compared to Placebo. Safety will be assessed by incidences of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), injection site reactions (ISRs) and other adverse events of special interest (AESIs), and the clinically significant laboratory values after injections of Engensis compared to Placebo. Exploratory endpoints include assessment of muscle function using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and ALSFRS-R subscores for Fine and Gross Motor Function; muscle strength by quantitative testing using handheld dynamometry (HHD) and the Accurate Test of Limb Isometric Strength (ATLIS) where available; quality of life using the ALS Assessment Questionnaire (ALSAQ-40); patient global impression of change (PGIC), clinical global impression of change (CGIC), and clinical global impression of severity (CGIS); and evaluation of lung function using Slow Vital Capacity (SVC). Muscle biopsies will be performed during the study for future biomarker analyses.
Eligibility
Inclusion Criteria:
1. Clinically definite or probable Amyotrophic Lateral Sclerosis (ALS) or laboratory-supported probable ALS as defined in the revised El Escorial/Airlie House diagnostic criteria 2. The site of onset of ALS symptoms is a limb and experiencing symptoms of lower motor dysfunction (e.g., weakness, atrophy, cramps, poor circulation, etc.) with upper motor neuron symptoms (e.g., weakness, brisk reflexes, spasticity) 3. Onset of ALS symptoms ≤ 4 years 4. Slow Vital Capacity (SVC) ≥ 50% of predicted value at Screening 5. Not taking riluzole, or on a stable dose (defined as no noted toxicities) for at least 30 days prior to Screening and throughout the study 6. Not taking edaravone or on a maintenance cycle for at least 30 days prior to Screening and throughout the study 7. For females of childbearing potential, a negative urine pregnancy test at Screening and on Day 0 8. Male Participants and their female partners must agree to use double-barrier contraception during the study or provide proof of postmenopausal state (minimum 1 year) or surgical sterility 9. Male Participants must not donate sperm during the study 10. Female Participants must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, or surgically sterile for at least 3 months, or agree to use double-barrier contraception from 28 days prior to randomization (Day 0) and/or their last confirmed menstrual period prior to study randomization (whichever is longer) until the end of the study 11. Capable of complying and willing to comply with the requirements and restrictions in the informed consent form and this protocol 12. Willing to forgo new experimental ALS treatments for at least 6 months following randomization Exclusion Criteria:
1. Progressive or degenerative neurological disorder such as Alzheimer's disease, Parkinson's disease, vascular dementia, multiple sclerosis, and other neurological or vascular disorders felt by the Investigator to preclude participation 2. Requires tracheotomy ventilation or noninvasive ventilation related to bulbar function 3. Evidence by physical examination, history, or laboratory evaluation of significant concomitant disease with a life expectancy of < 6 months at Screening 4. INR values >2.0 5. Platelet count <100,000/µL 6. Inflammatory disorder of the blood vessels (inflammatory angiopathy or vasculitis, such as Buerger's disease) 7. Active infection (chronic infection or severe active infection that may compromise the Participant's wellbeing or participation in the study in the Investigator's judgment) 8. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis) 9. Positive human immunodeficiency virus (HIV) or human T-cell lymphotrophic virus (HTLV) I/II test at Screening 10. Active acute or chronic hepatitis B 11. Active hepatitis C 12. Immunosuppression due to underlying disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) or to currently receiving immunosuppressive drugs, (e.g., chemotherapy, corticosteroids) or to radiation therapy 13. Stroke or myocardial infarction within 3 months prior to Screening 14. Active deep vein thrombosis 15. Recent history (< 3 years) or presence of cancer except basal cell carcinoma or squamous cell carcinoma of the skin that was excised and has shown no evidence of recurrence for at least 1 year 16. Major psychiatric disorder diagnosed in the past 6 months that has not been stabilized or in the Investigator's opinion would not allow the patient to participate in the scheduled procedures 17. Use of an investigational drug for the treatment of ALS in the past 30 days or 5 half-lives (if available), whichever is longer, or previous participation in a clinical study with Engensis 18. Stem cell administration for investigational treatment of ALS or other conditions in the 6 months prior to Screening
Details
Collaborator(s)
  • Helixmith Co., Ltd.
Trial Protocol as Published on Clinicaltrials.gov
NCT04632225 (First Published: 10/29/2020)